ATA9952002A - Verwendung eines antikörpers gerichtet gegen lewis-antigene - Google Patents

Verwendung eines antikörpers gerichtet gegen lewis-antigene

Info

Publication number
ATA9952002A
ATA9952002A AT0099502A AT9952002A ATA9952002A AT A9952002 A ATA9952002 A AT A9952002A AT 0099502 A AT0099502 A AT 0099502A AT 9952002 A AT9952002 A AT 9952002A AT A9952002 A ATA9952002 A AT A9952002A
Authority
AT
Austria
Prior art keywords
antigene
directed against
antibody directed
against lewis
lewis
Prior art date
Application number
AT0099502A
Other languages
English (en)
Other versions
AT413486B (de
Original Assignee
Igeneon Krebs Immuntherapie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AT0099502A priority Critical patent/AT413486B/de
Application filed by Igeneon Krebs Immuntherapie filed Critical Igeneon Krebs Immuntherapie
Priority to EP03762553A priority patent/EP1517922A2/de
Priority to PCT/EP2003/006912 priority patent/WO2004005349A2/en
Priority to JP2004518630A priority patent/JP2006510578A/ja
Priority to CA002488885A priority patent/CA2488885A1/en
Priority to US10/519,323 priority patent/US7527789B2/en
Priority to AU2003258498A priority patent/AU2003258498A1/en
Publication of ATA9952002A publication Critical patent/ATA9952002A/de
Application granted granted Critical
Publication of AT413486B publication Critical patent/AT413486B/de
Priority to US12/391,226 priority patent/US20090181030A1/en
Priority to AU2010203050A priority patent/AU2010203050C1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT0099502A 2002-07-03 2002-07-03 Verwendung eines antikörpers gerichtet gegen lewis-antigene AT413486B (de)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AT0099502A AT413486B (de) 2002-07-03 2002-07-03 Verwendung eines antikörpers gerichtet gegen lewis-antigene
PCT/EP2003/006912 WO2004005349A2 (en) 2002-07-03 2003-06-30 Preparation based on an antibody directed against a tumor-associated glycosylation such as lewis structures
JP2004518630A JP2006510578A (ja) 2002-07-03 2003-06-30 腫瘍関連グリコシル化に対する抗体に基づく製剤の使用
CA002488885A CA2488885A1 (en) 2002-07-03 2003-06-30 Preparation based on an antibody directed against a tumor-associated glycosylation such as lewis structures
EP03762553A EP1517922A2 (de) 2002-07-03 2003-06-30 Auf einem gegen eine tumorassoziierte glycosylierung wie lewis-strukturen gerichteten antikörper basierende herstellung
US10/519,323 US7527789B2 (en) 2002-07-03 2003-06-30 Use of a preparation based on an antibody directed against a tumor-associated glycosylation
AU2003258498A AU2003258498A1 (en) 2002-07-03 2003-06-30 Preparation based on an antibody directed against a tumor-associated glycosylation such as Lewis structures
US12/391,226 US20090181030A1 (en) 2002-07-03 2009-02-23 Use of a preparation based on an antibody directed against a tumor-associated glycosylation
AU2010203050A AU2010203050C1 (en) 2002-07-03 2010-07-19 Preparation based on an antibody directed against a tumor-associated glycosylation such as Lewis structures

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0099502A AT413486B (de) 2002-07-03 2002-07-03 Verwendung eines antikörpers gerichtet gegen lewis-antigene

Publications (2)

Publication Number Publication Date
ATA9952002A true ATA9952002A (de) 2005-08-15
AT413486B AT413486B (de) 2006-03-15

Family

ID=30004242

Family Applications (1)

Application Number Title Priority Date Filing Date
AT0099502A AT413486B (de) 2002-07-03 2002-07-03 Verwendung eines antikörpers gerichtet gegen lewis-antigene

Country Status (7)

Country Link
US (2) US7527789B2 (de)
EP (1) EP1517922A2 (de)
JP (1) JP2006510578A (de)
AT (1) AT413486B (de)
AU (2) AU2003258498A1 (de)
CA (1) CA2488885A1 (de)
WO (1) WO2004005349A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT413487B (de) 2002-08-12 2006-03-15 Igeneon Krebs Immuntherapie Verwendung von antikörpern gegen ein tumor-assoziiertes antigen
AT500648B1 (de) * 2002-08-12 2010-03-15 Igeneon Krebs Immuntherapie Set zur behandlung von krebspatienten
WO2005118802A2 (en) * 2004-06-03 2005-12-15 The Regents Of The University Of California Targeting pseudotyped retroviral vectors
MX350957B (es) 2011-11-23 2017-09-27 Medimmune Llc Moleculas de union especificas para her3 y usos de las mismas.
WO2015048008A2 (en) 2013-09-24 2015-04-02 Medimmune, Llc Binding molecules specific for her3 and uses thereof
SG11201607258SA (en) * 2014-04-10 2016-10-28 Obi Pharma Inc Antibodies, pharmaceutical compositions and uses thereof
WO2015157634A1 (en) 2014-04-11 2015-10-15 Kolltan Pharmaceuticals, Inc. Anti-erbb antibodies and methods of use thereof
GB201515094D0 (en) * 2015-08-25 2015-10-07 Univ Nottingham Sialyl-di-lewis a as expressed on glycoproteins but not glycolipids as a functional cancer target and antibodies thereto

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164489A (en) * 1988-05-23 1992-11-17 Board Of Regents, University Of Texas System Lung growth stimulatory and inhibitory factors for carcinoma tumor cells
DE4006308A1 (de) * 1990-02-28 1991-08-29 Sandoz Ag Verwendung des monoklonalen antikoerpers br 55.2 gegen kleinzelliges lungenkarzinom
US6121233A (en) 1991-04-19 2000-09-19 John L. Magnani Methods for the inhibition of cancer metastasis mediated by endothelial adhesion molecules
EP0521692A3 (en) 1991-07-02 1993-02-03 The Biomembrane Institute Inhibition of tumor cell metastasis potential and invasiveness by chemically-defined oligosaccharides, their derivatives, mimetics and antibodies directed to them
ATE188708T1 (de) * 1991-08-21 2000-01-15 Novartis Ag Antikörperderivate
DE19531348A1 (de) * 1995-08-25 1997-02-27 Gsf Forschungszentrum Umwelt Antikörper mit zwei oder mehr Spezifitäten zur selektiven Eliminierung von Zellen in vivo
GEP20104998B (en) * 1999-06-25 2010-06-10 Genentech Inc Humanized antibody which binds erbb2 and blocks activation by ligand receptor of erbb2 (variants) and use of the composition comprising these antibodies methods for treating cancer
WO2001070268A1 (en) * 2000-03-22 2001-09-27 Glaxo Group Limited Pharmaceutical comprising an agent that blocks the cell cycle and an antibody
AU1091802A (en) * 2000-10-20 2002-04-29 Chugai Pharmaceutical Co Ltd Degraded agonist antibody
PT1392359E (pt) 2001-05-11 2010-01-27 Ludwig Inst For Cancer Res Ltd Proteínas de ligação específica e suas utilizações
AT500648B1 (de) * 2002-08-12 2010-03-15 Igeneon Krebs Immuntherapie Set zur behandlung von krebspatienten

Also Published As

Publication number Publication date
AU2010203050A1 (en) 2010-08-12
AU2010203050B2 (en) 2012-06-07
US20050226880A1 (en) 2005-10-13
US7527789B2 (en) 2009-05-05
JP2006510578A (ja) 2006-03-30
AT413486B (de) 2006-03-15
AU2003258498A1 (en) 2004-01-23
EP1517922A2 (de) 2005-03-30
WO2004005349A2 (en) 2004-01-15
CA2488885A1 (en) 2004-01-15
US20090181030A1 (en) 2009-07-16
WO2004005349A3 (en) 2004-10-28
AU2010203050C1 (en) 2012-11-08

Similar Documents

Publication Publication Date Title
ATE501174T1 (de) Antikörper gegen madcam
DE60333189D1 (de) Elektromagnetischer dämpfer
NO20043996L (no) Fremgangsmate for frembringelse av API'er
ATE419849T1 (de) Diaminotriazole derivate und deren verwendung als protein kinase inhibitoren
DE60326970D1 (de) Gegen gewebefaktor gerichtete antikörper als antikoagulantien
ATE471344T1 (de) Antikörper gegen vla-1
NO20044347L (no) Anti-alfavbeta6-antistoff
CY2015050I2 (el) Βελτιστοποιημενη εκφραση της hpv 45 l1 σε ζυμη
DE60305388D1 (de) Elektromagnetische Wellenabsorber
ATE464068T1 (de) Antikörper gegen opgl
ATE452891T1 (de) Pyrimidopyrimidone als kinaseinhibitoren
DE60336123D1 (de) Heftinstrument
DK1599504T3 (da) Modificeret antistof
DE60229509D1 (de) Anti-osteopontin-antikörper und dessen verwendung
PT1481407E (pt) Transformador
ITTO20020622A1 (it) Gruppo integrato puleggia-smorzatore torsionale
DE60304985D1 (de) Toiletteneinheit eines Flugzeuges
DE60322544D1 (de) Glycinamid-derivate als raf-kinase-hemmer
DE502004011575D1 (de) Verwendung von Dioldimerfettsäureestern
ATA9952002A (de) Verwendung eines antikörpers gerichtet gegen lewis-antigene
DE602004030435D1 (de) Verwendung eines metallkatalysators
ITTO20020621A1 (it) Gruppo integrato puleggia-smorzatore torsionale
DE60316134D1 (de) Substituierte aminoisoxazolinderivate und ihre verwendung als antidepressiva
ATE394140T1 (de) Verwendung neuer etonogestrelester
FI20021792A7 (fi) Jousi- ja kielisoitinrakenne

Legal Events

Date Code Title Description
EIH Change in the person of patent owner
MM01 Lapse because of not paying annual fees

Effective date: 20160815